Brief: Polyphor Announces Acceptance Of Balixafortide Abstract At ASCO 2020 Virtual Scientific Program
14/05/2020 06:07
May 14 (Reuters) - POLYPHOR AG POLN.S :
* POLYPHOR ANNOUNCES ACCEPTANCE OF BALIXAFORTIDE ABSTRACT AT
THE
AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) 2020 VIRTUAL
SCIENTIFIC PROGRAM
Source text for Eikon: ID:nEQ7QVQR9a
Further company coverage: POLN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Spexis AG
See all newsBrief: Spexis AG: Expects Audit Of 2023 Financials Will Not Be Completed By 31 July 2024
Brief: Spexis Launches Appeal Against Six Exchange Regulation Decision To Suspend Trading Of Its Shares.
Brief: Spexis AG- Audit Costs Have Not Been Approved Yet And Further Extension May Be Required
Brief: Spexis Announces CFO Hernan Levett Has Decided To Pursue New Career Outside Company
Brief: Spexis: Total Loss Of CHF 3.9 Mln In H1 2023